Get the Stockscreener App
30.59
3.37%
0.9809
Procept Biorobotics Corp stock is traded at $30.59, with a volume of 779.29K.
It is up +3.37% in the last 24 hours and down -5.56% over the past month.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
See More
Previous Close:
$29.61
Open:
$29.94
24h Volume:
779.29K
Relative Volume:
0.56
Market Cap:
$1.71B
Revenue:
$249.12M
Net Income/Loss:
$-90.19M
P/E Ratio:
-17.99
EPS:
-1.7
Net Cash Flow:
$-88.21M
1W Performance:
+0.98%
1M Performance:
-5.56%
6M Performance:
-45.07%
1Y Performance:
-59.02%
1-Day Range:
$29.65
$31.34
1-Week Range:
$28.76
$32.05
52-Week Range:
$27.80
$75.29
Procept Biorobotics Corp Stock (PRCT) Company Profile
Name
Procept Biorobotics Corp
Sector
Industry
Phone
(650) 232-9832
Address
150 BAYTECH DRIVE, SAN JOSE
Compare PRCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRCT
Procept Biorobotics Corp
|
30.59 | 1.65B | 249.12M | -90.19M | -88.21M | -1.70 |
|
ABT
Abbott Laboratories
|
107.42 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.36 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.74 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.35 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.83 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Procept Biorobotics Corp Stock (PRCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-25 | Initiated | UBS | Buy |
| Dec-08-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-02-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-09-25 | Initiated | Stephens | Overweight |
| Jul-07-25 | Initiated | Oppenheimer | Perform |
| Dec-02-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Initiated | Jefferies | Hold |
| Aug-11-23 | Initiated | Piper Sandler | Overweight |
| May-31-23 | Initiated | William Blair | Outperform |
| Oct-31-22 | Initiated | BTIG Research | Neutral |
| Oct-25-22 | Initiated | Truist | Buy |
| Sep-02-22 | Initiated | Wells Fargo | Overweight |
| Jul-15-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Goldman | Neutral |
| Oct-11-21 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | SVB Leerink | Outperform |
View All
Procept Biorobotics Corp Stock (PRCT) Latest News
PROCEPT BioRobotics to Report Q4 2025 Financial Results and Host Investor Day Event in February 2026 - Quiver Quantitative
Surgery robot firm PROCEPT plans Feb. 25 investor day at Nasdaq HQ - Stock Titan
Did AquaBeam Milestones and Options Activity Just Shift PROCEPT BioRobotics' (PRCT) Investment Narrative? - simplywall.st
A Look At PROCEPT BioRobotics (PRCT) Valuation As Regulatory And Clinical Catalysts Draw Investor Focus - simplywall.st
First Week of March 20th Options Trading For PROCEPT BioRobotics (PRCT) - InteractiveCrypto
Will PROCEPT BioRobotics Corporation benefit from current market trendsBreakout Watch & Expert-Curated Trade Recommendations - bollywoodhelpline.com
Is PROCEPT BioRobotics Corporation stock a buy or sell2025 EndofYear Setup & Long-Term Safe Return Strategies - bollywoodhelpline.com
Promising growth forecasts leading to analysts’ optimism for Procept Biorobotics (PRCT) - MSN
FMR LLC Reduces Stake in PROCEPT BioRobotics Corp by 42.10% - GuruFocus
US Market Wrap: What risks investors should watch in PROCEPT BioRobotics Corporation stock - Bộ Nội Vụ
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Assessing PROCEPT BioRobotics (PRCT) Valuation As Fresh Analyst Downgrade Meets Confident Long-Term Growth Views - simplywall.st
Peregrine Capital Management LLC Purchases Shares of 188,219 PROCEPT BioRobotics Corporation $PRCT - MarketBeat
PROCEPT BioRobotics (NASDAQ:PRCT) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Will PROCEPT BioRobotics Corporation stock outperform value stocksJuly 2025 Pullbacks & Real-Time Buy Zone Alerts - Улправда
Procept BioRobotics initiated with a buy at UBS - MSN
PROCEPT BioRobotics (NASDAQ:PRCT) Trading Down 7.1%Here's Why - MarketBeat
Is Wall Street’s Split View On PROCEPT BioRobotics (PRCT) Revealing Aquablation’s True Strategic Position? - simplywall.st
Truist Maintains Buy Rating on Procept BioRobotics (PRCT) Amid MedTech Sector Rotation - Finviz
Will PROCEPT BioRobotics Corporation stock return to pre crisis levels2025 Investor Takeaways & Capital Protection Trading Alerts - Улправда
ISRG Trading 4% Below All-Time High: Should You Buy the Stock Now? - Nasdaq
PROCEPT BioRobotics Corporation (PRCT) Stock Analysis: A 53% Potential Upside in the Surgical Robotics Arena - DirectorsTalk Interviews
PROCEPT BioRobotics Corporation $PRCT Shares Purchased by Chicago Capital LLC - MarketBeat
PROCEPT BioRobotics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Best Robotics Stocks To ConsiderDecember 26th - MarketBeat
How Investors Are Reacting To PROCEPT BioRobotics (PRCT) UBS Coverage Initiation And 2027 Profitability Outlook - simplywall.st
What Wall Street predicts for PROCEPT BioRobotics Corporation stock priceConsumer Goods Stocks & Free Record-Breaking Gains - Bollywood Helpline
Promising Growth Forecasts Leading to Analysts' Optimism for Procept Biorobotics (PRCT) - Finviz
Promising Growth Forecasts Leading to Analysts’ Optimism for Procept Biorobotics (PRCT) - Yahoo Finance
15 Most Promising Mid-Cap Healthcare Stocks Under $50 - Insider Monkey
Aug EndMonth: What Wall Street predicts for PROCEPT BioRobotics Corporation stock priceJuly 2025 Gainers & AI Driven Stock Movement Reports - Улправда
Transcript : PROCEPT BioRobotics Corporation Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-02-2025 08 - marketscreener.com
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Procept BioRobotics price target lowered to $47 from $50 at Truist - TipRanks
Truist Financial Has Lowered Expectations for PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price - MarketBeat
Truist Financial Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Cuts Target Price to $47 - 富途牛牛
Truist Securities Adjusts Price Target on PROCEPT BioRobotics to $47 From $50, Maintains Buy Rating - marketscreener.com
PROCEPT BioRobotics (PRCT) Stock Analysis: Eyeing a 41% Upside with Robust Revenue Growth - directorstalkinterviews.com
3 Underrated Robotics Stocks Poised for Huge Gains - Investing.com
PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Shareholders Might Be Looking For Exit - 富途牛牛
Squarepoint Ops LLC Decreases Stake in PROCEPT BioRobotics Corporation $PRCT - MarketBeat
PROCEPT BioRobotics (NASDAQ:PRCT) Downgraded by Wall Street Zen to Sell - MarketBeat
PROCEPT BioRobotics Corporation $PRCT Shares Bought by Eventide Asset Management LLC - MarketBeat
Bellevue Group AG Acquires 74,355 Shares of PROCEPT BioRobotics Corporation $PRCT - MarketBeat
UBS Initiates Coverage of PROCEPT BioRobotics (PRCT) with Buy Recommendation - Nasdaq
UBS initiates Procept BioRobotics stock with Buy rating on utilization growth - Investing.com Australia
PRCT FinancialsIncome Statement - Quiver Quantitative
Procept BioRobotics initiated with a Buy at UBS - TipRanks
Procept Biorobotics Corp Stock (PRCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.21%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):